Audentes Therapeutics, Inc.
Total raised
$108 M
2 rounds on record
Latest round
$65 M
Oct 2015
First round on record
Nov 2014
Today
Private
No later event on record
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Audentes Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2015).
SEC Form D · Oct 2015
The industry group it chose in its notices: Biotechnology.
SEC Form D · Oct 2015
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
14 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| 5AM Co-Investors III, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| 5AM Partners III, LLC | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| 5am Ventures III, L.P. | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Deerfield Management Company, L.P. | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Deerfield Mgmt III, L.P. | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Deerfield Mgmt L.P. | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Deerfield Private Design Fund III, L.P. | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Deerfield Special Situations Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Louis G. Lange | Person | not stated | not stated | Held Series B preferred stock, director (Form 3, 2016) | SEC Form 3 |
| Orbimed Advisors LLC | Fund or asset manager | not stated | not stated | Held Series Seed, A, B and C preferred stock, 10% owner, director (Form 3, 2016) | SEC Form 3 |
| OrbiMed Capital GP IV LLC | Fund or asset manager | not stated | not stated | Held Series Seed, A, B and C preferred stock, 10% owner, director (Form 3, 2016) | SEC Form 3 |
| Versant Side Fund IV, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Versant Venture Capital IV, L.P. | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
| Versant Ventures IV, LLC | Venture capital | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2016) | SEC Form 3 |
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Matthew Patterson | Executive officer | Oct 2015 |
| Jonathan Leff | Director | Oct 2015 |
| Jonathan Silverstein | Director | Oct 2015 |
| Kush Parmar | Director | Oct 2015 |
| Louis Lange | Director | Oct 2015 |
| Matthew Patterson | Director | Oct 2015 |
| Steve Squinto | Director | Oct 2015 |
| Thomas Schuetz | Director | Oct 2015 |
| Thomas Woiwode | Director | Oct 2015 |
| Jonathan SIlverstein | Director | Dec 2014 |